News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty
Photo taken from: Debyani Chakravarty / Twitter
Jul 17, 2023, 09:59

Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty

My OncoKB people: Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC.

Looking fwd to it getting tumor agnostic approval based on Alison Schram work showing 42% ORR in PDAC (& 35% in NSCLC).

 

Source: Debyani Chakravarty / Twitter

FDA OncoDaily Oncology zenocutuzumab
Special Coverage
Blog
Sep 1, 2024, 18:14
Lung Cancer Europe at 2024 Congress of ESMO
Insight
Sep 1, 2024, 18:05
Stephen Liu: The role of adjuvant chemotherapy when adjuvant ALK TKI is planned
Blog
Sep 1, 2024, 17:48
Jakob Nikolas Kather: The first ESMO conference purely on AI and Digital Oncology
Insight
Sep 1, 2024, 17:36
Boost your Lung Cancer Research skills at EGFR Resisters Research Summit
Blog
Sep 1, 2024, 17:28
Residual breast tissue after mastectomy and reconstruction
Blog
Sep 1, 2024, 17:18
Miriam Mutebi: The consequences of communication breakdown
Blog
Sep 1, 2024, 17:14
Ovarian Protection Strategies for Breast Cancer Patients In Africa
Career
Sep 1, 2024, 17:07
Mohammad Arifuzzaman: I will be starting my lab at Weill Cornell Medicine this fall
Blog
Sep 1, 2024, 17:03
Vivek Subbiah: Our WHY is YOU!
Blog
Sep 1, 2024, 17:01
Nina Fuller-Shavel: Delighted to announce the launch of our new integrative oncology project
Blog
Sep 1, 2024, 17:00
Douglas Flora: Join Faith Community Pharmacy for a Happy Hour with a Purpose
Blog
Sep 1, 2024, 16:54
Paulo Luz: AI for Patients with HER2+ Breast Cancer - HER2pCRPredict